Osteoporosis drugs compared for side effects, efficacy

November 28, 2013, Loyola University Health System

A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic acid caused more flulike symptoms. These findings were presented recently at the American Society for Bone and Mineral Research's annual meeting.

Researchers performed a retrospective chart review and survey of 107 patients to compare the efficacy, patient satisfaction, cost and known of denosumab versus , including muscle pain, back pain and flulike symptoms. The denosumab and zoledronic acid groups were statistically similar in all areas but spine (increased 0.060 g/cm2 versus 0.021 g/cm2, respectively) and flulike symptoms (none versus 29 percent of patients).

"Both groups of patients were satisfied with their treatment despite the discrepancies in the drugs," said Kellen Sheedy, first author and Stritch School of Medicine student.

The FDA approved denosumab in 2010 for with osteoporosis. It is injected subcutaneously (60 mg) every six months. The treatment works by inhibiting and fracture risk.

Zoledronic acid was approved by the FDA in 2007 for osteoporosis. This treatment is administered intravenously (5 mg) once every 12 months. It is the most potent of the drugs in its class, and it works by interfering with the bone-breakdown process.

"This study helped us quantify the efficacy and adverse effects of these two drugs providing further guidance for physicians who prescribe these treatments," said Pauline Camacho, MD, study investigator and director of the Osteoporosis & Metabolic Bone Disease Center at Loyola University Health System. "While this was the first head-to-head comparison of these two treatments, larger prospective studies will be needed to confirm these findings."

Explore further: Risk of osteoporosis drug's side effects not significant, researchers find

Related Stories

Risk of osteoporosis drug's side effects not significant, researchers find

October 31, 2013
The risks of developing kidney failure and a calcium deficiency from the popular osteoporosis drug zoledronic acid are extremely rare, according to researchers at Loyola University Health System (LUHS). These findings were ...

Common osteoporosis drug slows formation of new bone

April 17, 2013
Although the drug zoledronic acid slows bone loss in osteoporosis patients, it also boosts levels of a biomarker that stops bone formation, according to a recent study accepted for publication in The Endocrine Society's Journal ...

Denosumab superior to zoledronic acid for breast cancer patients with bone metastases

August 14, 2012
Treatment with denosumab resulted in a greater reduction in skeletal-related events in patients with breast cancer that spread to the bones compared with zoledronic acid, while also maintaining health-related quality of life, ...

Drug prevents bone loss side effects of breast cancer medication

October 10, 2011
A new study has found that an osteoporosis drug protects against the bone damaging side effects of certain breast cancer medications. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, ...

New osteoporosis drug combination outperforms current alternatives

May 14, 2013
A combination of two FDA-approved osteoporosis drugs with different mechanisms of action was found to increase bone density better than treatment with either drug alone in a small clinical trial. As reported in paper receiving ...

Recommended for you

New study offers insights on genetic indicators of COPD risk

January 16, 2018
Researchers have discovered that genetic variations in the anatomy of the lungs could serve as indicators to help identify people who have low, but stable, lung function early in life, and those who are particularly at risk ...

Previous influenza virus exposures enhance susceptibility in another influenza pandemic

January 16, 2018
While past exposure to influenza A viruses often builds immunity to similar, and sometimes different, strains of the virus, Canadian researchers are calling for more attention to exceptions to that rule.

Don't hold your nose and close your mouth when you sneeze, doctors warn

January 15, 2018
Pinching your nose while clamping your mouth shut to contain a forceful sneeze isn't a good idea, warn doctors in the journal BMJ Case Reports.

New antifungal provides hope in fight against superbugs

January 12, 2018
Microscopic yeast have been wreaking havoc in hospitals around the world—creeping into catheters, ventilator tubes, and IV lines—and causing deadly invasive infection. One culprit species, Candida auris, is resistant ...

Dengue takes low and slow approach to replication

January 11, 2018
A new study reveals how dengue virus manages to reproduce itself in an infected person without triggering the body's normal defenses. Duke researchers report that dengue pulls off this hoax by co-opting a specialized structure ...

Different strains of same bacteria trigger widely varying immune responses

January 11, 2018
Genetic differences between different strains of the same pathogenic bacterial species appear to result in widely varying immune system responses, according to new research published in PLOS Pathogens.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.